Podcast: Play in new window | Download

Subscribe: Apple Podcasts | Android | RSS

This week on The Green Rush, our hosts Nick and Anne are chatting with David Johnson, CEO of Enveric Biosciences, a patient-first biotechnology company developing rigorously tested, novel cannabinoid medicines to improve quality of life for cancer patients. 

It’s been a while since the Green Rush team has talked about CBD so we used this opportunity to get an update on the state of the space including how CBD is fitting into the existing medical landscape, the ways that technology is progressing the validation of these molecules and what the market could look like in the next several years. We also explore Enveric’s business model and how they compare to other players in the industry as well as key news from the industry including Jazz Pharmaceuticals acquisition of GW Pharma. 

Now on to our conversation with David Johnson of Enveric Biosciences.

David Johnson, Chairman and CEO of Enveric Biosciences

Former CEO of Convatec, oversaw the $4.1B spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies.

Links and mentions in the show

• https://www.enveric.com/ 
• Diverse Biotech Partnership
• PureForm Partnership

Links to the guest’s company and social media accounts

• David Johnson’s LinkedIn: https://www.linkedin.com/in/david-johnson-235b0224/ 

Show Credits:

This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:

Twitter: @The_GreenRush 

Instagram: @thegreenrush_podcast

LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/ 

Facebook: https://www.facebook.com/TheGreenRushPodcast/ 

YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true